Trial Profile
The impact of DPP-4 inhibitor on daily glucose profile and coronary plaque character in impaired glucose tolerance patients with coronary artery disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Mar 2022
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary)
- Indications Glucose intolerance
- Focus Pharmacodynamics
- Acronyms VOGUE-KOBE
- 15 Mar 2022 According to UMIN, date of closure to data entry is 31 Mar 2019, date of trial data considered complete is 31 Mar 2019 and date of analysis conclusion is 31 Mar 2019.
- 15 Mar 2022 Status changed from recruiting to completed.
- 11 Sep 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.